AI Diagnostics Adoption & Accuracy
Where AI Dx is real — and where it’s hype.
A defensible view of AI diagnostics adoption, accuracy and reimbursement — across imaging, pathology and digital biomarkers.
"Which AI diagnostic categories are scaling — and which are stuck in pilots?"
Imaging AI (radiology, ophthalmology) is scaling. Pathology AI is in clinical adoption. Digital biomarkers (skin, voice) remain mostly piloting.
AI diagnostics has moved past hype in radiology and pathology. The teams winning are those that integrate into existing workflow and align with active reimbursement codes.
What we’re seeing in the data.
Radiology AI mainstream
Stroke, breast, lung at scale.
Pathology AI scaling
Workflow + accuracy now compelling.
Reimbursement remains uneven
CPT codes lag adoption.
How to think about it.
-
01
Segment by modality
Radiology / pathology / cardiac / digital biomarkers.
-
02
Score adoption maturity
Scaled / scaling / piloting.
-
03
Map reimbursement
CPT codes, payer coverage.
-
04
Forecast tipping points
Reg + reimbursement + workflow.
What separates a good answer from a defensible one.
Standalone AI fails.
Real-world ≠ trial.
Continuous-learning AI.
Where the signal comes from.
Common questions.
Where to invest in AI Dx?
Workflow-integrated radiology and pathology with active reimbursement.
Standalone AI viable?
Rarely; embedded wins.
Want this answered on your data?
We build decision systems on top of analyses like this — so the next question takes minutes, not weeks.
Talk to a strategist